
Sign up to save your podcasts
Or


In this episode, oncology pharmacists Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, explore and challenge common assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, offering insights on patient selection, trial nuances, toxicity management, and real-world decision-making.
Presenters:
Rodney Hunter, PharmD, BCOP
Julia L. Ziegengeist, PharmD, BCOP
Link to full program:
https://bit.ly/46SPGlU
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
By Decera Clinical Education4.9
1010 ratings
In this episode, oncology pharmacists Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, explore and challenge common assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, offering insights on patient selection, trial nuances, toxicity management, and real-world decision-making.
Presenters:
Rodney Hunter, PharmD, BCOP
Julia L. Ziegengeist, PharmD, BCOP
Link to full program:
https://bit.ly/46SPGlU
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

78,705 Listeners

37,593 Listeners

43,646 Listeners

320 Listeners

503 Listeners

59 Listeners

3,367 Listeners

113,450 Listeners

46 Listeners

53 Listeners

61 Listeners

35 Listeners

196 Listeners

46 Listeners